Mirabegron (25mg) in patients with overactive bladder is effective and safe in real life practice

Mirabegron (25mg) in patients with overactive bladder is effective and safe in real life practice

Bibliographic Details
Main Authors:	Yuan Chi Shen, Yao Chi Chuang
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2016-06-01
Series:	Urological Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S1879522616302743

Similar Items

Mirabegron, a breakthrough in overactive bladder syndrome?
by: Almudena Maestro Nombela, et al.
Published: (2017-05-01)

Patient utilization survey of mirabegron prescribed for overactive bladder
by: Päivi Rahkola-Soisalo, et al.
Published: (2019-03-01)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
by: Sharaf A, et al.
Published: (2017-02-01)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
by: Sara J. Allison, et al.
Published: (2018-12-01)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
by: Marilena Gubbiotti, et al.
Published: (2019-01-01)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
by: Makhani A, et al.
Published: (2020-04-01)

Effect of mirabegron in patients with myasthenia gravis disease and overactive bladder symptoms
by: M.G. Çulha, et al.
Published: (2020-07-01)

Re: Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder
by: Sinharib Çitgez
Published: (2016-12-01)

Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder
by: Mehmet Solakhan, et al.
Published: (2019-09-01)

Preliminary experience and possible predictors of successful mirabegron treatment for overactive bladder
by: Tsai-Feng Chen, et al.
Published: (2017-09-01)

Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?
by: Ömer Acar, et al.
Published: (2019-06-01)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
by: Andersson KE
Published: (2013-04-01)

Mirabegron: A first-in-class beta-3 agonist for overactive bladder
by: Suruchi Aditya, et al.
Published: (2015-01-01)

Clinical use of the β adrenoceptor agonist mirabegron in patients with overactive bladder syndrome
by: Monika Vij, et al.
Published: (2015-10-01)

Mirabegron escalation to 50 mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder
by: Chun-Hou Liao, et al.
Published: (2019-03-01)

Mirabegron: a review of recent data and its prospects in the management of overactive bladder
by: Emilio Sacco, et al.
Published: (2012-12-01)

Mirabegron: the review of current knowledge of safety and efficacy in the relief of overactive bladder symptoms
by: Tomasz Aleksiewicz, et al.
Published: (2018-08-01)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
by: Yankai Xu, et al.
Published: (2017-09-01)

Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder
by: Cheng-Ling Lee, et al.
Published: (2020-01-01)

Mirabegron for Overactive Bladder: A Novel, First-in-Class β3- Agonist Therapy
by: Mohammed Imran, et al.
Published: (2013-09-01)

Mirabegron does not decrease urinary neurotrophin's levels in overactive bladder patients despite symptomatic improvement
by: Ana Sara dos Santos Ferreira
Published: (2019)

Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: A pilot study
by: Marilena Gubbiotti, et al.
Published: (2019-05-01)

The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder
by: Ganesh Thiagamoorthy, et al.
Published: (2016-02-01)

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies
by: Andrea Tubaro, et al.
Published: (2017-06-01)

Perspectives on mirabegron in the treatment of overactive bladder syndrome: A new beta-3 adrenoceptor agonist
by: Chia-Hao Kuei, et al.
Published: (2015-03-01)

Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
by: Lee RT, et al.
Published: (2013-10-01)

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
by: Seong Cheol Kim, et al.
Published: (2021-05-01)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
by: Jameel Nazir, et al.
Published: (2018-09-01)

The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study
by: A. Zachariou, et al.
Published: (2018-06-01)

Mirabegron &ndash; a selective &szlig;3-adrenoreceptor agonist for the treatment of overactive bladder
by: Bhide AB, et al.
Published: (2012-07-01)

Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients
by: Chung-Cheng Wang, et al.
Published: (2019-01-01)

Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence
by: Mete Özkidik, et al.

Mirabegron add-on therapy to tamsulosin in men with overactive bladder: Post-hoc analyses of efficacy from the MATCH study
by: H. Kakizaki, et al.
Published: (2020-07-01)

Investigation of the reasons for withdrawal from long-term treatment with mirabegron of treatment-naïve Japanese female patients with overactive bladder in the real-world clinical setting
by: Yoshinori Tanaka, et al.
Published: (2019-01-01)

Older patients with idiopathic, wet overactive bladder and multiple comorbidities: May mirabegron represent a first choice pharmacological agent?
by: M. Gubbiotti, et al.
Published: (2020-07-01)

Real-World Effects of Mirabegron in Patients with Chronic Neurogenic Detrusor Overactivity – A Retrospective Cohort Study
by: Krebs J, et al.
Published: (2020-05-01)

Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study
by: Se Yun Kwon, et al.
Published: (2020-07-01)

Real-life patient experiences of TTNS in the treatment of overactive bladder syndrome
by: Manon te Dorsthorst, et al.
Published: (2021-08-01)

Effects of ba-wei-die-huang-wan on cyclophosphamide-induced ongoing bladder overactivity and acidic atp solution-induced provoking of bladder overactivity
by: Wei-Chia Lee, et al.
Published: (2015-06-01)

Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials
by: Hann-Chorng Kuo, et al.
Published: (2015-03-01)